

# William J Murphy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3733067/publications.pdf>

Version: 2024-02-01

156  
papers

8,363  
citations

44069

48  
h-index

53230

85  
g-index

157  
all docs

157  
docs citations

157  
times ranked

11387  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Possible Role for Anti-idiotypic Antibodies in SARS-CoV-2 Infection and Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 394-396.	27.0	70
2	Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. <i>Nature Communications</i> , 2022, 13, 1511.	12.8	77
3	Retinoic acid signaling acts as a rheostat to balance Treg function. , 2022, 19, 820-833.		8
4	Inhaled recombinant human IL-15 in dogs with naturally occurring pulmonary metastases from osteosarcoma or melanoma: a phase 1 study of clinical activity and correlates of response. , 2022, 10, e004493.		10
5	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. <i>Blood</i> , 2021, 137, 1090-1103.	1.4	8
6	The emerging roles of the gut microbiome in allogeneic hematopoietic stem cell transplantation. <i>Gut Microbes</i> , 2021, 13, 1966262.	9.8	4
7	NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms. , 2021, , 3-31.		2
8	Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms. <i>Cancers</i> , 2021, 13, 729.	3.7	3
9	Re-Examining the Paradigm of Impaired Healing in the Aged Murine Excision Wound Model. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1071-1075.e4.	0.7	3
10	Skin-Resident $\hat{I}^2$ AR Signaling Delays Burn Wound Healing. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2098-2101.e4.	0.7	1
11	Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects. <i>Blood</i> , 2021, 138, 2583-2588.	1.4	8
12	Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target. <i>Frontiers in Immunology</i> , 2021, 12, 670309.	4.8	11
13	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. , 2021, 9, e002627.		15
14	Activation Status Dictates the Function of Unlicensed Natural Killer Cells. <i>Blood Advances</i> , 2021, 5, 4219-4232.	5.2	1
15	The urgent need for more basic research on SARS-Cov2 infection and vaccines in assessing potential psychoneurological effects using maternal immune activation (MIA) and other preclinical modeling. <i>Brain, Behavior, and Immunity</i> , 2021, 97, 1-3.	4.1	2
16	Mechanisms by Which Obesity Promotes Acute Graft-Versus-Host Disease in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 752484.	4.8	9
17	AML Cell Vaccines Co-Expressing CD80 and IL-15/IL-15 Receptor Alpha Induce Activation and Cytolytic Activity in Post Remission Autologous Patient PBMC Ex Vivo. <i>Blood</i> , 2021, 138, 1706-1706.	1.4	0
18	Obesity induces gut microbiota alterations and augments acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	29

#	ARTICLE	IF	CITATIONS
19	PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment. <i>Frontiers in Immunology</i> , 2020, 11, 590568.	4.8	9
20	Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. <i>Nature Communications</i> , 2020, 11, 4591.	12.8	81
21	IL-2 and Anti-TGF- $\beta$ Promote NK Cell Reconstitution and Anti-tumor Effects after Syngeneic Hematopoietic Stem Cell Transplantation. <i>Cancers</i> , 2020, 12, 3189.	3.7	8
22	Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. , 2020, 8, e001355.		55
23	Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 49.	3.9	122
24	Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. <i>PLoS ONE</i> , 2020, 15, e0224775.	2.5	15
25	Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 475-492.	27.6	80
26	Minimal PD-1 expression in mouse and human NK cells under diverse conditions. <i>Journal of Clinical Investigation</i> , 2020, 130, 3051-3068.	8.2	90
27	Title is missing!. , 2020, 15, e0224775.		0
28	Title is missing!. , 2020, 15, e0224775.		0
29	Title is missing!. , 2020, 15, e0224775.		0
30	Title is missing!. , 2020, 15, e0224775.		0
31	Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. , 2019, 7, 291.		4
32	Natural Killer Cells in GvHD and GvL. , 2019, , 275-292.		5
33	Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 242-252.	1.8	15
34	Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality. <i>Journal of Immunology</i> , 2019, 202, 2795-2805.	0.8	10
35	The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1247.	7.4	69
36	Targeting PI3K $\beta$ function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	4.7	9

#	ARTICLE	IF	CITATIONS
37	Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 49-60.	1.8	33
38	The complicated effects of obesity on cancer and immunotherapy. <i>Immunotherapy</i> , 2019, 11, 11-14.	2.0	10
39	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 141-151.	30.7	539
40	Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells. <i>Cancers</i> , 2019, 11, 85.	3.7	18
41	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. <i>JCI Insight</i> , 2019, 4, .	5.0	8
42	Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway. <i>JCI Insight</i> , 2019, 4, .	5.0	57
43	Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1922-1922.	1.4	0
44	Obesity induced T cell dysfunction and implications for cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2018, 51, 181-186.	5.5	52
45	Donor HSCs with a preexisting ASXL1-mutation led to the development of FLT3-ITD positive AML in the donor and FLT3-ITD negative AML in the recipient after unrelated transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 499-502.	2.4	3
46	Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas. <i>Journal of Surgical Research</i> , 2018, 223, 207-214.	1.6	20
47	Making a Better Hematopoietic Stem Cell "Timing Is Everything. <i>New England Journal of Medicine</i> , 2018, 378, 89-91.	27.0	1
48	Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 221-229.	1.2	28
49	Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1259-1270.	0.8	54
50	Obesity as an immune-modifying factor in cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2018, 104, 487-497.	3.3	25
51	Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. <i>Theranostics</i> , 2018, 8, 3611-3628.	10.0	58
52	A possible new pathway in natural killer cell activation also reveals the difficulty in determining human NK cell function in cancer. , 2018, 6, 79.		7
53	Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. <i>Developmental and Comparative Immunology</i> , 2018, 87, 64-74.	2.3	31
54	The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2017, 75, 268-279.	2.8	62

#	ARTICLE	IF	CITATIONS
55	Leveraging natural killer cells for cancer immunotherapy. <i>Immunotherapy</i> , 2017, 9, 487-497.	2.0	26
56	Stimulating Innate Immunity to Enhance Radiation Therapyâ€“Induced Tumor Control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 362-373.	0.8	43
57	Therapeutic Efficacy of Fresh, Allogeneic Mesenchymal Stem Cells for Severe Refractory Feline Chronic Gingivostomatitis. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1710-1722.	3.3	74
58	Human and feline adipose-derived mesenchymal stem cells have comparable phenotype, immunomodulatory functions, and transcriptome. <i>Stem Cell Research and Therapy</i> , 2017, 8, 69.	5.5	42
59	Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 313-324.	3.1	75
60	Western Dietâ€“Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment. <i>American Journal of Pathology</i> , 2017, 187, 1800-1813.	3.8	90
61	Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy. , 2017, 5, 33.		43
62	Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 30-37.	2.0	10
63	Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. , 2017, 5, 98.		101
64	Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. <i>JCI Insight</i> , 2017, 2, e90521.	5.0	83
65	Licensing delineates helper and effector NK cell subsets during viral infection. <i>JCI Insight</i> , 2017, 2, .	5.0	30
66	High fluence light emitting diodeâ€“generated red light modulates characteristics associated with skin fibrosis. <i>Journal of Biophotonics</i> , 2016, 9, 1167-1179.	2.3	33
67	Canine cancer immunotherapy studies: linking mouse and human. , 2016, 4, 97.		86
68	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016, 127, 2144-2154.	1.4	145
69	Preclinical modeling of hematopoietic stem cell transplantation â€“ advantages and limitations. <i>FEBS Journal</i> , 2016, 283, 1595-1606.	4.7	17
70	Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. <i>Oncolimmunology</i> , 2016, 5, e1075114.	4.6	47
71	Mouse host unlicensed NK cells promote donor allogeneic bone marrow engraftment. <i>Blood</i> , 2016, 127, 1202-1205.	1.4	19
72	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. <i>Blood</i> , 2016, 128, 1013-1017.	1.4	95

#	ARTICLE	IF	CITATIONS
73	Immunoregulatory pathways following strong inflammatory processes markedly impair CD4+ T cell responses. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2249-2252.	3.3	1
74	Being "penny-wise but pound foolish" in cancer immunotherapy research: the urgent need for mouse cancer models to reflect human modifying factors. , 2016, 4, 88.		5
75	Natural killer cell immunotherapy to target stem-like tumor cells. , 2016, 4, 19.		41
76	Therapeutic Efficacy of Fresh, Autologous Mesenchymal Stem Cells for Severe Refractory Gingivostomatitis in Cats. <i>Stem Cells Translational Medicine</i> , 2016, 5, 75-86.	3.3	88
77	Immune targeting of cancer stem cells in gastrointestinal oncology. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, S1-S10.	1.4	12
78	Models to Study NK Cell Biology and Possible Clinical Application. <i>Current Protocols in Immunology</i> , 2015, 110, 14.37.1-14.37.14.	3.6	24
79	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. <i>Blood</i> , 2015, 126, 1621-1628.	1.4	104
80	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	1.4	101
81	Reprint of: Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S19-S24.	2.0	26
82	Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity. <i>Immunity</i> , 2015, 43, 240-250.	14.3	83
83	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. <i>Blood</i> , 2015, 125, 3335-3346.	1.4	55
84	Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells. <i>Oncotarget</i> , 2015, 4, e1036212.	4.6	64
85	CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery. <i>Journal of Controlled Release</i> , 2015, 220, 253-264.	9.9	26
86	Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1541-1552.	4.2	9
87	NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. <i>Journal of Immunology</i> , 2015, 195, 4010-4019.	0.8	173
88	Obesity and cancer immunotherapy toxicity. <i>Immunotherapy</i> , 2015, 7, 319-322.	2.0	20
89	Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 24-29.	2.0	87
90	ASXL1-Mutated Donor HSCs Evolved into FLT3-ITD Positive AML in the Unrelated Donor and FLT3-ITD Negative AML in the Recipient after Transplant. <i>Blood</i> , 2015, 126, 5403-5403.	1.4	2

#	ARTICLE	IF	CITATIONS
91	Attenuated Age-Impact on Systemic Inflammatory Markers in the Presence of a Metabolic Burden. PLoS ONE, 2015, 10, e0121947.	2.5	5
92	Resveratrol Prevents High Fluence Red Light-Emitting Diode Reactive Oxygen Species-Mediated Photoinhibition of Human Skin Fibroblast Migration. PLoS ONE, 2015, 10, e0140628.	2.5	11
93	Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality. Blood, 2015, 126, 147-147.	1.4	0
94	Bystander Activation and Anti-Tumor Effects of CD8+ T Cells Following Interleukin-2 Based Immunotherapy Is Independent of CD4+ T Cell Help. PLoS ONE, 2014, 9, e102709.	2.5	26
95	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. Journal of Clinical Investigation, 2014, 124, 4867-4876.	8.2	173
96	Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer, 2014, 14, 756.	2.6	23
97	Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/±CD40 Therapy. Journal of Immunology, 2014, 192, 5821-5829.	0.8	60
98	Natural Killer Cell Subsets Differentially Reject Embryonic Stem Cells Based on Licensing. Transplantation, 2014, 97, 992-998.	1.0	21
99	Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunology, Immunotherapy, 2014, 63, 21-28.	4.2	78
100	Increased Antitumor Effects Using IL-2 with Anti-TGF-β <sup>2</sup> Reveals Competition between Mouse NK and CD8 T Cells. Journal of Immunology, 2014, 193, 1709-1716.	0.8	39
101	Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels. Biology of Blood and Marrow Transplantation, 2014, 20, 1899-1904.	2.0	24
102	Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. Journal of Experimental Medicine, 2014, 211, 2373-2383.	8.5	124
103	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood, 2014, 123, 3988-3998.	1.4	179
104	Treatment of chronic graft-versus-host disease with bortezomib. Blood, 2014, 124, 1677-1688.	1.4	72
105	Positive and Negative Regulation by NK Cells in Cancer. Critical Reviews in Oncogenesis, 2014, 19, 57-66.	0.4	52
106	Immunoediting and Antigen Loss: Overcoming the Achilles Heel of Immunotherapy with Antigen Non-Specific Therapies. Frontiers in Oncology, 2013, 3, 197.	2.8	36
107	Ageing predisposes to acute inflammatory induced pathology after tumor immunotherapy. Journal of Experimental Medicine, 2013, 210, 2223-2237.	8.5	132
108	Impact of aging in cancer immunotherapy. Oncoimmunology, 2013, 2, e27186.	4.6	20

#	ARTICLE	IF	CITATIONS
109	Murine natural killer cell licensing and regulation by T regulatory cells in viral responses. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7401-7406.	7.1	38
110	Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood, 2013, 122, 2125-2134.	1.4	47
111	Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses. Blood, 2013, 122, 1518-1521.	1.4	22
112	Influenza infection results in local expansion of memory CD8+ T cells with antigen non-specific phenotype and function. Clinical and Experimental Immunology, 2013, 175, 79-91.	2.6	51
113	Organ-Specific Protection By Bortezomib On The Treatment Of Cutaneous Chronic and Acute GvHD. Blood, 2013, 122, 4473-4473.	1.4	0
114	Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model. Blood, 2013, 122, 292-292.	1.4	0
115	Natural Killer Cell Licensing Delineates NK "Helper/Repair" and NK "Effector/Suppressor" Subsets During Viral Infections. Blood, 2013, 122, 13-13.	1.4	1
116	Evidence That Novel NK-NK Cell Subset Regulation Exists With Regard To Effects In Tumor and Viral Models. Blood, 2013, 122, 1038-1038.	1.4	0
117	IFN- $\gamma$ Receptor-Deficient Donor T Cells Mediate Protection from Graft-versus-Host Disease and Preserve Graft-versus-Tumor Responses after Allogeneic Bone Marrow Transplantation. Journal of Immunology, 2012, 189, 2033-2042.	0.8	13
118	Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy. Blood, 2012, 119, 3073-3083.	1.4	76
119	Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing. Blood, 2012, 119, 1590-1598.	1.4	45
120	Autoimmune T Cells Lured to a FASL Web of Death by MSCs. Cell Stem Cell, 2012, 10, 485-487.	11.1	5
121	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood, 2012, 119, 1570-1580.	1.4	221
122	NK Cells "From Bench to Clinic. Biology of Blood and Marrow Transplantation, 2012, 18, S2-S7.	2.0	58
123	Mechanical Disruption of Tumors by Iron Particles and Magnetic Field Application Results in Increased Anti-Tumor Immune Responses. PLoS ONE, 2012, 7, e48049.	2.5	29
124	Advances in graft-versus-host disease biology and therapy. Nature Reviews Immunology, 2012, 12, 443-458.	22.7	746
125	The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. Journal of Immunotoxicology, 2012, 9, 248-258.	1.7	34
126	Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy?. International Reviews of Immunology, 2011, 30, 238-293.	3.3	5



#	ARTICLE	IF	CITATIONS
127	Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1754-1764.	2.0	12
128	Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. <i>Blood</i> , 2011, 117, 7032-7041.	1.4	44
129	'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. <i>Nature Immunology</i> , 2010, 11, 321-327.	14.5	239
130	Organ-Specific Protection from CD8+ T Cell-Mediated Acute Skin GVHD by Bortezomib Administration Correlates with Decreased IL-6.. <i>Blood</i> , 2010, 116, 3735-3735.	1.4	7
131	Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19455-19460.	7.1	77
132	Blood Stem Cell Transplantation in Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1638-1639.	2.0	3
133	Natural Killer (NK) Cell Recovery After Bone Marrow Transplantation in Mice: Early Emergence of a Novel Ly49+ Stage in Differentiation Independent of MHC Haplotype.. <i>Blood</i> , 2009, 114, 4477-4477.	1.4	1
134	NK Cell-Mediated Rejection of Bone Marrow Cells- In Vivo Evidence of NK Cell Subset Licensing.. <i>Blood</i> , 2009, 114, 3537-3537.	1.4	0
135	Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell-Mediated Antitumor Responses. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1088-1099.	2.0	42
136	Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition. <i>Journal of Immunology</i> , 2008, 180, 163-170.	0.8	138
137	Regulatory and Conventional CD4+ T Cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression after Immunotherapy. <i>Journal of Immunology</i> , 2008, 180, 2981-2988.	0.8	21
138	Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. <i>Blood</i> , 2008, 112, 1522-1529.	1.4	31
139	The Antioxidant Inflammation Modulator, CDDO-Me Promotes Myelopoiesis in Mice.. <i>Blood</i> , 2008, 112, 2335-2335.	1.4	0
140	Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Annual Review of Immunology</i> , 2007, 25, 139-170.	21.8	454
141	IFN- $\gamma$ mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. <i>Nature Medicine</i> , 2007, 13, 354-360.	30.7	163
142	Dissociating GVT from GVHD in Murine BMT Models through TNF- $\alpha$ Dependent CD4+ T Cell Mediated GVHD and IFN- $\gamma$ Dependent CD8+ T Cell Mediated Anti-Tumor Effects.. <i>Blood</i> , 2007, 110, 69-69.	1.4	0
143	CD4+CD25+Foxp3+ Regulatory T Cell Function Outside the Immune System: Differential Regulation of Hematopoietic Progenitor Cell Populations.. <i>Blood</i> , 2007, 110, 64-64.	1.4	0
144	Positive and negative regulation of Natural Killer cells: Therapeutic implications. <i>Seminars in Cancer Biology</i> , 2006, 16, 367-382.	9.6	44

#	ARTICLE	IF	CITATIONS
145	Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5460-5465.	7.1	131
146	Removal of Donor CD4+ T Cells Markedly Promotes Graft-Versus-Tumor (GVT) Effects and Inhibits GVHD-Dependent Toxicity Associated with Prolonged Bortezomib Administration after Allogeneic BMT.. Blood, 2006, 108, 3160-3160.	1.4	0
147	In Vivo CpG Administration Accelerates Graft-Versus-Host Disease (GVHD) Lethality by Toll-Like Receptor 9 (TLR9) Ligation of Host Antigen-Presenting Cells (APCs) and Promotes Allogeneic Bone Marrow (BM) Rejection by TLR9 Ligation of Donor APCs.. Blood, 2006, 108, 446-446.	1.4	0
148	Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood, 2005, 106, 3293-3299.	1.4	110
149	Immunomodulatory Effects of the Triterpenoid CDDO after Allogeneic Bone Marrow Transplantation in Mice: Reduction of Acute Graft-Versus-Host Disease Lethality.. Blood, 2005, 106, 1316-1316.	1.4	0
150	Suppression of NK Cell-Mediated Bone Marrow Cell Rejection by CD4+CD25+ Regulatory T Cells: Linkage of Adaptive to Innate Responses.. Blood, 2005, 106, 2195-2195.	1.4	0
151	Antibodies to CD40 Promote Dendritic Cell Recovery and Anti-Tumor Effects after Syngeneic Bone Marrow Transplant (BMT).. Blood, 2005, 106, 1305-1305.	1.4	12
152	Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8120-8125.	7.1	238
153	The immunobiology of natural killer cells and bone marrow allograft rejection. Biology of Blood and Marrow Transplantation, 2003, 9, 727-741.	2.0	53
154	Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses. Journal of Immunology, 2003, 170, 2727-2733.	0.8	105
155	Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood, 2001, 97, 3132-3137.	1.4	139
156	Synergistic effects of in vivo depletion of Ly-49A and Ly-49G2 natural killer cell subsets in the rejection of H2b bone marrow cell allografts. Blood, 2000, 95, 3840-3844.	1.4	14